文献速递前列腺癌

PSMA PET与MRI预测中高危前列腺癌早期生化进展

Predicting early outcomes in patients with intermediate- and high-risk prostate cancer using prostate-specific membrane antigen positron emission tomography and magnetic resonance imaging.
PubMed 文献 · BJU Int · 2021-06-16

这项观察性研究纳入493例接受机器人辅助腹腔镜根治性前列腺切除术(RARP)及扩大盆腔淋巴结清扫的中危不利或高危局限性前列腺癌患者,评估初始PSA、活检Grade Group、mpMRI T分期及PSMA PET淋巴结状态对术后早期生化进展的预测价值。中位随访12.6个月,多因素分析显示上述指标均为早期生化进展的独立预测因素。

要点

  • 初始PSA、活检GG≥4、mpMRI≥rT3及PSMA PET miN1是RARP后早期生化进展的独立预测因素。
  • mpMRI显示≥rT3b者早期生化进展风险显著高于rT2(OR 4.78)。
  • PSMA PET提示miN1者早期生化进展风险约为miN0的2.94倍。

核心结论

  • 初始PSA值、活检GG≥4、mpMRI≥rT3病变及PSMA PET miN1是RARP后早期生化进展的预测因素。

研究设计与样本

  • 观察性研究纳入493例因不利中危或高危局限性前列腺癌接受RARP及扩大盆腔淋巴结清扫的患者。
  • 采用Cox回归分析评估生化进展的预测因素,包括初始PSA、活检GG、mpMRI T分期及PSMA PET淋巴结状态。

主要发现

  • 无生化进展患者的中位随访时间为12.6个月(IQR 7.5-22.7)。
  • 初始PSA每翻倍,生化进展OR为1.22(95%CI 1.07-1.40;P=0.004)。
  • 活检GG≥4 vs GG1-2的OR为1.83(95%CI 1.18-2.85;P=0.007)。
  • mpMRI rT3a vs rT2的OR为2.13(95%CI 1.39-3.27;P=0.001),≥rT3b vs rT2的OR为4.78(95%CI 3.20-7.16;P<0.001)。
  • PSMA PET miN1的OR为2.94(95%CI 2.02-4.27;P<0.001)。

临床怎么用

  • 可利用初始PSA、活检GG、mpMRI T分期及PSMA PET淋巴结状态识别RARP后早期生化进展高风险患者。
  • 识别高风险患者有助于根治性治疗决策时的患者咨询及现代(新)辅助和系统治疗的患者选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To identify predictors of early oncological outcomes in patients who opt for robot-assisted laparoscopic radical prostatectomy (RARP) for localized prostate cancer (PCa), including conventional prognostic variables as well as multiparametric magnetic resonance imaging (mpMRI) and prostate-specific membrane antigen (PSMA) positron emission tomography (PET). PATIENTS AND METHODS: This observational study included 493 patients who underwent RARP and extended pelvic lymph node dissection (ePLND) for unfavourable intermediate- or high-risk PCa. Outcome measurement was biochemical progression of disease, defined as any postoperative prostate-specific antigen (PSA) value ≥0.2 ng/mL, or the start of additional treatment. Cox regression analysis was performed to assess predictors for biochemical progression, including initial PSA value, biopsy Grade Group (GG), T-stage on mpMRI, and lymph node status on PSMA PET imaging (miN0 vs miN1). RESULTS: The median (interquartile range) total follow-up of all included patients without biochemical progression was 12.6 (7.5-22.7) months. When assessing biochemical progression after surgery, initial PSA value (per doubling; odds ratio [OR] 1.22, 95% confidence interval [CI] 1.07-1.40; P = 0.004), biopsy GG ≥4 vs GG 1-2 (OR 1.83, 95% CI 1.18-2.85; P = 0.007), T-stage on mpMRI (rT3a vs rT2: OR 2.13, 95% CI 1.39-3.27; P = 0.001; ≥rT3b vs rT2: OR 4.78, 95% CI 3.20-7.16; P < 0.001) and miN1 on PSMA PET imaging (OR 2.94, 95% CI 2.02-4.27; P < 0.001) were independent predictors of early biochemical progression of disease. CONCLUSION: Initial PSA value, biopsy GG ≥4, ≥rT3 disease on mpMRI and miN1 disease on PSMA PET were predictors of early biochemical progression after RARP. Identifying these patients with an increased risk of early biochemical progression after surgery may have major implications for patient counselling in radical treatment decisions and on patient selection for modern (neo-)adjuvant and systematic treatments.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Meijer D, van Leeuwen PJ, Donswijk ML, et al. Predicting early outcomes in patients with intermediate- and high-risk prostate cancer using prostate-specific membrane antigen positron emission tomography and magnetic resonance imaging. BJU Int. 2021. PMID: 34028165. doi:10.1111/bju.15492

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。